Page 2 - Biocon Ltd News

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw

After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase

Biocon Q3FY26 results: Revenue up 9%, net profit rises on generics push

Board gives in-principle nod to make Biocon Biologics a wholly owned subsidiary as Q3 net profit climbs to Rs 143.8 crore

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,